Here are Tuesday's biggest analyst calls of the day: Nvidia, Broadcom, Tesla, Lowe's, Disney, Intel & more
Here are the biggest calls on Wall Street on Tuesday. Goldman Sachs initiates Aevex as buy Goldman says the drones company is “unique.” “We initiate coverage of Aevex (AVEX) with a Buy rating and $34 12-month price target, based on 5.4X CY27 EV/Sales.” Read more . Citi reiterates Broadcom as buy Citi raised its price target on Broadcom to $500 per share from $475 ahead of earnings in early June. “We raise our PT to $500 based on a 20x multiple applied to FY28 EPS of $25, vs prior 30x but rolling forward to FY28 (from F27) to reflect increased earnings visibility. Maintain Buy and reiterate #1 semis pick in 2026.” Wells Fargo reiterates Nvidia as overweight Wells raised its price target to $315 per share from $265. “We’re positive on the NVDA F1Q27 set-up.” Read more. Bernstein reiterates Disney as outperform Bernstein says it’s sticking with its outperform rating. “With concerns around the Experiences segment partially alleviated following the FYQ2 print, we believe the setup for Disney could improve if (1) Experiences segment delivers on the renewed expectations for the summer despite macro headwinds, and (2) DTC margins expand beyond the initial 10% guidance for the year, with clear momentum for further improvement. It doesn’t need to be great—just better.” Wells Fargo reiterates Tesla as underweight Wells says its checks show Tesla deliveries are trending better year over year. “Of the 4 mkts we track, April TSLA deliveries are trending +7% y/y & -47% m/m.” Susquehanna reiterates Nvidia as positive The firm raised its price target to $275 per share from $250. “NVIDIA reports earnings on Wednesday, May 20. We expect better results and guidance as GB300 continues to ramp through 1H26.” JPMorgan upgrades Braskem to overweight from neutral JPMorgan says the margin tailwinds are “unleased” for the chemical company. “We upgrade Braskem to Overweight, reflecting improved market fundamentals, tighter supply, and strengthened governance post restructuring.” JPMorgan upgrades Celanese to overweight from neutral JPMorgan upgraded the stock on valuation. “We rate Celanese Overweight for year-ahead performance. Celanese’s share price has moved lower (14%) from almost $69 last week versus the market, which is 2% higher.” JPMorgan initiates Kailera Therapeutics as overweight JPMorgan says the biotech company has a robust pipeline. “We are initiating coverage of Kailera Therapeutics (KLRA) with an Overweight rating and a $30 YE26 price target.” JPMorgan initiates Alamar Biosciences as overweight The firm says the life sciences company has a differentiated offering. “We are initiating coverage of Alamar Biosciences (ALMR) with an Overweight rating and a DCF-derived December 2026 PT of $30.” Truist upgrades Matador Resources to buy from hold Truist says investors should buy the dip in the oil exploration stock following earnings. “We upgrade MTDR t o Buy from Hold and increase our NAV-based PT to $67/shr from $60/ shr prior.” Wells Fargo initiates Spire as overweight Wells says the natural gas company has re-rating potential. “We are initiating coverage on SR with an Overweight rating and a $96 PT. Valuation is compelling at current levels, and we see an opportunity for a further re-rating from here, with an improving regulated profile.” Citi upgrades Lowe’s to buy from neutral Citi says it’s bullish ahead of earnings on May 20. “LOW should beat 1Q street estimates and continue to outperform the industry ( & HD) in 2026; (2) LOW is attractive to own in the current home improvement landscape – higher exposure to DIY/smaller projects and a lower SSS hurdle rate to leverage EBIT margin;” Read more. Benchmark initiates Insulet as buy Benchmark called the insulin pump manufacturer a “differentiated market leader.” “We are initiating coverage o f Insulet with a Buy rating and $250 price target. Insulet aims to maintain its position as the market leader in automated insulin delivery by leveraging its tubeless form factor, an established pharmacy distribution model, international footprint, and early entry into the rapidly growing Type 2 market.” Benchmark initiates MiniMed as buy The firm says the diabetes management company is firing on all cylinders. “We are initiating coverage of MiniMed Group with a Buy rating and $20 PT.” Benchmark initiates Dexcom as buy Benchmark says it’s bullish on the med tech company. “We are initiating coverage of Dexcom with a Buy rating and $77 price target.” Evercore ISI initiates Benitec Biopharma as overweight Evercore said in its initiation of Benitec that it has plenty of upside. “A Rare Disease Story Worth Chewing On.” Bank of America upgrades Bentley Systems to buy from neutral Bank of America reinstated coverage and upgraded the stock saying it’s “defensive.” “Vertical software vendors have faced a trial by fire this year with investors fearing that Agentic AI would automate applications they created for their respective industries. However, we think Bentley Systems, which designs software for infrastructure engineering, is a defensive play that can fend off AI.” Bank of America upgrades AutoDesk to buy from neutral Bank of America reinstated coverage and upgraded the stock, saying it has “technology that’s hard to copy and hard to beat.” “We reinstate design software leader Autodesk with a Buy rating and a $300 PO. In our view, Autodesk’s data, 3D context, and decade-long AI investment give it structural advantages that are hard to replicate.” Bernstein initiates Sunbelt as outperform Bernstein says the construction equipment rentals company has plenty more room to run. “We are initiating coverage on Sunbelt with an Outperform rating and a target price of $86, implying c20% upside to yesterday’s share price.” Deutsche Bank reiterates Intel as hold Deutsche raised its price target on the stock to $100 per share from $63. “Over the past ~month, reports of Intel’s Foundry business gaining customer traction have become much more frequent yielding a strong tailwind for INTC shares (+100% in last month).”
